CD74

CD74

a type II transmembrane protein present on B cells, monocytes, dendritic cells, and activated T cells; prevents binding of endogenous peptides; expressed in B-cell chronic lymphocytic leukemia, hairy cell leukemia, and large granular leukocyte lymphomas.
References in periodicals archive ?
CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52u CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279
Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists.
University of British Columbia researchers' discovery of the role played by the molecule CD74 could help immunologists investigate treatments that offer better immune responses against cancers, viruses and bacteria, and lead to more efficient vaccines.
For the assessment of monocyte antigen-presenting capacity, we analyzed 2 genes associated with major histocompatibility complex class II (MHCII), HLA-DRA (major histocompatibility complex, class II, DR alpha) and CD74 (CD74 molecule, major histocompatibility complex, class II invariant chain).
More recently, Paul has played a vital role operating the company's newest press investment; a Heidelberg Speedmaster CD74 10 colour perfector, which is one of the first of its kind in the country.
Expanded an ADC research collaboration with Genmab A/S under which Seattle Genetics' ADC technology will be utilized with Genmab's HuMax-CD74 antibody targeting CD74, which is expressed on a wide range of hematological malignancies and solid tumors; Seattle Genetics received an undisclosed upfront payment and has the right to exercise a co-development and co-commercialization option for any resulting ADC products at the end of phase I clinical development
Inhibitors, Pipeline Development 42 Figure 16: Pipeline, Global, First-in-Class CD74 Inhibitors, Pipeline Development 43 Figure 17: Pipeline, Global, First-in-Class Modulators of B7-Related Protein, Pipeline Development 45
Under the new agreement, Genmab has rights to utilize Seattle Genetics' ADC technology with HuMax-CD74, an antibody in pre-clinical development to target CD74, which is expressed on a wide range of hematological malignancies and solid tumors.
Inhibitors, Pipeline Development 42 Figure 16: Pipeline, Global, First-in-Class CD74 Inhibitors, Pipeline Development 43 Figure 17: Pipeline, Global, First-in-Class Modulators of B7-Related Protein, Pipeline Development 45 Figure 18: Pipeline, Global, First-in-class modulators of IL-21, Scientific Assessment 47 Figure 19: Pipeline, Global, First-in-class Modulators of IL-21, Pipeline Development 48 Figure 20: Pipeline, Global, First-in-Class Modulators of IL-17 , Pipeline Development 50 Figure 21: Pipeline, Global, First-in-Class High Mobility Box Protein 1 Inhibitors, Pipeline Development 52
The Company informed that the allowed claims cover the use of bispecific antibodies targeting CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, of immune cells, and CD20 to form a vaccine complex.
1,2,8] Immunophenotypically, the neoplastic B cells stain uniformly positive for most B-cell markers, such as CD20, CD45RA, CD79a, MB1, MB2, CDw75, and CD74, but they are negative for T-cell markers, myelomonocytic marker CD15, and activating marker CD30.